<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00716066</url>
  </required_header>
  <id_info>
    <org_study_id>2260.00</org_study_id>
    <secondary_id>NCI-2010-00403</secondary_id>
    <secondary_id>2260.00</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT00716066</nct_id>
  </id_info>
  <brief_title>Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy</brief_title>
  <official_title>High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects and how well carmustine, etoposide, cytarabine
      and melphalan together with antithymocyte globulin before a peripheral blood stem cell
      transplant works in treating patients with autoimmune neurologic disease that did not respond
      to previous therapy. In autoimmune neurological diseases, the patient's own immune system
      'attacks' the nervous system which might include the brain/spinal cord and/or the peripheral
      nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine,
      melphalan, and antithymocyte globulin, before a peripheral blood stem cell transplant weakens
      the immune system and may help stop the immune system from 'attacking' a patient's nervous
      system. When the patient's own (autologous) stem cells are infused into the patient they help
      the bone marrow make red blood cells, white blood cells, and platelets so the blood counts
      can improve.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Evaluate the safety of high-dose carmustine, etoposide, Ara-c (cytarabine) and melphalan
      (BEAM) and Thymoglobulin (antithymocyte globulin) as a high-dose immunosuppressive treatment
      (HDIT) regimen in patients with severe, refractory neurological autoimmune disease.

      SECONDARY OBJECTIVES:

      I. Evaluate disease responses and the duration of response to HDIT and autologous
      hematopoietic stem cell transplantation (HSCT).

      II. Determine the efficacy and safety of G-CSF (filgrastim) and prednisone or
      cyclophosphamide for hematopoietic stem mobilization in patients with neurological autoimmune
      diseases.

      OUTLINE:

      Patients receive carmustine intravenously (IV) on day -6, etoposide IV and cytarabine IV
      twice daily (BID) on days -5 to -2, melphalan IV on day -1, and antithymocyte globulin IV on
      days -2 and -1. Patients then undergo autologous or syngeneic peripheral blood stem cell
      transplant on day 0. Patients also receive prednisone orally (PO) once daily (QD) on days
      7-21, followed by 2 week taper.

      After completion of study treatment, patients are followed up at 3 months, 1 year, and then
      annually thereafter for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of grades 4-5 regimen-related toxicity as assessed by the Regimen Related Toxicity Scale</measure>
    <time_frame>Within 28 days post-transplant</time_frame>
    <description>Using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. The development of a grade 4 to 5 toxicity of any of the included major organ systems within the first 28 days after transplant will be defined as regimen-related toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease responses as assessed by clinical, laboratory and radiologic evaluation</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment kinetics</measure>
    <time_frame>Over first 60 days post-transplant</time_frame>
    <description>Monitored for engraftment kinetics of granulocytes, platelets and red cells post-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects achieving greater than or equal to 4.0 x 10(6) CD34+cells/kg, after up to two peripheral blood stem cell mobilizations</measure>
    <time_frame>Baseline to post mobilization, assessed up to 20 days after starting final mobilization (up to two mobilizations)</time_frame>
    <description>Efficacy of peripheral blood stem cell mobilization as evaluated by total number of harvested CD34+cells/kg, for autologous transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with an exacerbation of autoimmune disease symptoms secondary to G-CSF (filgrastim) during peripheral blood stem cell mobilization</measure>
    <time_frame>Baseline to post mobilization, assessed up to 20 days after starting final mobilization (up to two mobilizations)</time_frame>
    <description>Subjects are evaluated by standardized clinical neurologic tests specific to autoimmune disease type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-related mortality</measure>
    <time_frame>Within 100 days post-transplant</time_frame>
    <description>Defined as death within the first 100 days of transplant due to transplant-related complications.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Autoimmune Disease</condition>
  <arm_group>
    <arm_group_label>Treatment (immunosuppressive therapy followed by transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive carmustine IV on day -6, etoposide IV and cytarabine IV BID on days -5 to -2, melphalan IV on day -1 and antithymocyte globulin IV on days -2 and -1. Patients then undergo autologous or syngeneic peripheral blood stem cell transplant on day 0. Patients also receive prednisone PO QD on days 7-21, followed by 2 week taper.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (immunosuppressive therapy followed by transplant)</arm_group_label>
    <other_name>Antithymocyte Globulin</other_name>
    <other_name>Antithymocyte Serum</other_name>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>ATS</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous or syngeneic peripheral blood stem cell transplantation</description>
    <arm_group_label>Treatment (immunosuppressive therapy followed by transplant)</arm_group_label>
    <other_name>Autologous Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (immunosuppressive therapy followed by transplant)</arm_group_label>
    <other_name>BCNU</other_name>
    <other_name>Becenum</other_name>
    <other_name>Becenun</other_name>
    <other_name>BiCNU</other_name>
    <other_name>Bis(chloroethyl) Nitrosourea</other_name>
    <other_name>Bis-Chloronitrosourea</other_name>
    <other_name>Carmubris</other_name>
    <other_name>Carmustin</other_name>
    <other_name>Carmustinum</other_name>
    <other_name>FDA 0345</other_name>
    <other_name>Gliadel</other_name>
    <other_name>N,N'-Bis(2-chloroethyl)-N-nitrosourea</other_name>
    <other_name>Nitrourean</other_name>
    <other_name>Nitrumon</other_name>
    <other_name>SK 27702</other_name>
    <other_name>SRI 1720</other_name>
    <other_name>WR-139021</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (immunosuppressive therapy followed by transplant)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-Cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (immunosuppressive therapy followed by transplant)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (immunosuppressive therapy followed by transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (immunosuppressive therapy followed by transplant)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine Nitrogen Mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous or syngeneic peripheral blood stem cell transplantation</description>
    <arm_group_label>Treatment (immunosuppressive therapy followed by transplant)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (immunosuppressive therapy followed by transplant)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Syngeneic Bone Marrow Transplantation</intervention_name>
    <description>Undergo syngeneic bone marrow transplantation</description>
    <arm_group_label>Treatment (immunosuppressive therapy followed by transplant)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with an autoimmune disorder of the central or peripheral nervous system will
             be eligible; this will include:

               -  Primary Central Nervous System (CNS) vasculitis

               -  Rasmussen's encephalitis

               -  Autoimmune peripheral neuropathy (anti-Hu [Anna-1], anti-GM1 [GD1b], anti-MAG,
                  anti-ganglioside, anti-sulfatide)

               -  Autoimmune cerebellar degeneration

               -  Gait Ataxia with Late age Onset Polyneuropathy (GALOP)

               -  Stiff Person Syndrome

               -  Chronic Inflammatory Demyelinating Polyneuropathy

               -  Myasthenia Gravis

               -  Lambert-Eaton myasthenic syndrome

               -  Human T-cell lymphotropic virus (HTLV)-1-associated myelopathy (HAM) / tropical
                  spastic paraparesis (TSP)

               -  Opsoclonus / myoclonus (anti-Ri)

               -  Neuromyelitis optica

               -  Multiple sclerosis (Only patients with relapsing/remitting MS will be included.)

               -  Other central or peripheral nervous system autoimmune diseases as approved by
                  study neurologists and the Fred Hutchinson Cancer Research Center (FHCRC) faculty
                  at Patient Care Conference (PCC)

          -  Patients must satisfy the criteria for a diagnosis of one of the severe neurological
             autoimmune disorders outlined

          -  Evidence of disease activity as outlined (e.g. gadolinium enhancement on magnetic
             resonance imaging of the brain or clinical progression)

          -  Patients must have failed at least 2 lines of stand therapy as outlined for the
             specific diseases

          -  DONOR: Sibling of any patient enrolled on this protocol proven by ABO typing, human
             leukocyte antigen (HLA) typing and variable number tandem repeat (VNTR) analysis to be
             syngeneic with the patient (e.g. identical twin)

          -  DONOR: Willing to undergo multiple apheresis procedures (except donors &lt; 12 years who
             will undergo bone marrow harvests)

        Exclusion Criteria:

          -  Pregnancy or expressed plans to become pregnant within 1 year of the procedure

          -  Patients who are serologically positive for human immunodeficiency virus (HIV)

          -  Patients with pulmonary, cardiac, hepatic or renal impairment that would limit their
             ability to receive cytoreductive therapy and compromise their survival; this should
             include patients with any of the following:

               -  Severe pulmonary dysfunction associated with a carbon monoxide diffusing capacity
                  (DLCO) (corrected for hemoglobin) &lt; 60%, or requires supplemental oxygen

               -  Uncontrolled malignant arrhythmias, or clinical evidence of congestive heart
                  failure (New York class III-IV) or ejection fraction &lt; 50%

               -  Renal disease with estimated glomerular filtration rate (GFR) by creatinine
                  clearance or iothalamate clearance &lt; 50 ml/min/1.73 m^2 body surface area

               -  Serum glutamate pyruvate transaminase (SGPT)/aspartate aminotransferase (AST) &gt; 3
                  times normal or direct bilirubin greater than 2.5 mg/dL on two repeated tests

          -  Active uncontrolled infection

          -  Demonstrated lack of compliance with prior medical care

          -  Patients whose life expectancy is limited by illness other than their neurological
             condition

          -  Patients with evidence of myelodysplasia

          -  Active malignancy (excluding localized squamous cell or basal cell carcinoma of the
             skin)

          -  DONOR: Inadequate documentation that donor and recipient are syngeneic

          -  DONOR: Donors who do not fulfill criteria as apheresis donors as established by
             institutional guidelines

          -  DONOR: Concordant for autoimmune neurological disease(s) as determined by neurological
             evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Georges</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard A. Nash</last_name>
      <phone>720-754-4800</phone>
      <email>Richard.Nash@Healthonecares.com</email>
    </contact>
    <investigator>
      <last_name>Richard A. Nash</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George E. Georges</last_name>
      <phone>206-667-6886</phone>
      <email>ggeorges@fhcrc.org</email>
    </contact>
    <investigator>
      <last_name>George E. Georges</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center-First Hill</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122-4307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Bowen</last_name>
      <phone>206-320-2200</phone>
    </contact>
    <investigator>
      <last_name>James Bowen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2008</study_first_submitted>
  <study_first_submitted_qc>July 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2008</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cortisone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

